Skip to main content
    U

    Utah Medical Products Inc (UTMD)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $72.02
    -0.34 (-0.47%)

    Market Cap: $206.03M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Utah Medical Products Inc (UTMD) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Utah Medical Products (UTMD) has a market cap of $206.03M and an enterprise value of $121.01M. It holds $85.02M more cash than debt, 41.27% of its market cap. It kept 30.48% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 41.27% below the market cap, as cash exceeds debt.

    Market Cap$206.03M
    Enterprise Value$121.01M
    Latest price (Nov 17, 2026)$72.02

    Key Dates

    The next earnings report is expected on Jan 27, 2027, covering the quarter ending Dec 31, 2026. The next ex-dividend date is Dec 17, 2026.

    Next Earnings DateJan 27, 2027 (expected)
    Last Earnings DateOct 22, 2026
    Next Ex-Dividend DateDec 17, 2026
    Next Payment DateJan 5, 2027
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 0.13% in the quarter ended Sep 30, 2026 and shrank 4.38% a year over 2 years.

    Shares Outstanding3.18M
    Shares Change (YoY)-0.84%
    Shares Change (QoQ)-0.13%
    Share Count Growth (2Y CAGR)-4.38%

    Valuation Ratios

    Sales and book value multiples are 6.6x and 1.9x. Its year-end P/E ranged from 15.6x to 28.0x from 2016 to 2025.

    P/E Ratio21.6x
    P/S Ratio6.6x
    P/B Ratio1.9x
    P/TBV Ratio2.2x
    P/FCF Ratio21.1x
    P/OCF Ratio18.0x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 11.9x EBITDA and 13.3x free cash flow.

    EV / Earnings11.4x
    EV / Sales3.5x
    EV / EBITDA11.9x
    EV / EBIT9.3x
    EV / FCF13.3x

    Price Statistics

    The stock is up 31.37% over 52 weeks and trades 1.42% below its 50-day average.

    Beta (1Y)0.25
    52-Week Change+31.37%
    1-Month Change-3.39%
    3-Month Change+0.28%
    6-Month Change+13.53%
    5-Year Change-29.70%
    10-Year Change+9.53%
    Total Return (1Y)+33.63%
    Total Return (3Y CAGR)-3.81%
    Total Return (5Y CAGR)-7.06%
    Return vs SPY (1Y)+21.61%
    Max Drawdown (1Y)-13.24%
    Max Drawdown (3Y)-38.54%
    Sharpe Ratio (1Y)1.00
    Correlation with SPY (1Y)0.12
    50-Day Average$73.06
    200-Day Average$68.37
    52-Week Range$52.65 to $76.89
    RSI (14 Days)48.2
    Average Volume (20 Days)32.85K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 21.23x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio21.23x
    Quick Ratio19.00x
    Debt / Equity0.00x
    Debt / EBITDA0.01x
    Debt / FCF0.02x

    Returns and Efficiency

    Return on invested capital is 6.74% over the last 12 months, against a 5-year average of 7.55%.

    Return on Equity (ROE)8.63%
    Return on Assets (ROA)8.28%
    Return on Invested Capital (ROIC)6.74%
    Return on Capital Employed (ROCE)10.48%
    ROE (5Y Average)12.49%
    ROA (5Y Average)11.78%
    ROIC (5Y Average)7.55%
    Asset Turnover0.28x
    Inventory Turnover1.51x
    Receivables Turnover9.28x
    Cash Conversion Cycle250 days

    Taxes

    Income tax took 17.98% of pretax income over the last 12 months.

    Income Tax (TTM)$2.33M
    Effective Tax Rate17.98%

    Scores

    UTMD has an Altman Z-Score of 29.19, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.

    Altman Z-Score29.19
    Altman Z ZoneSafe
    Piotroski F-Score6 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $34.92M over the last 12 months is down 9.62% from the 12 months before.

    Revenue$34.92M
    Revenue Growth (YoY)-9.62%
    Gross Profit$19.61M
    Operating Income$10.45M
    Pretax Income$12.97M
    Net Income$10.64M
    EBITDA$14.92M
    EBIT$12.97M
    Reported EPS (TTM)$3.34

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 95.94% of the $128.50M in total assets.

    Cash and Equivalents$85.20M
    Total Debt$180.00K
    Net Cash$85.02M
    Net Cash Per Share$26.74
    Working Capital$95.89M
    Shareholder Equity$123.28M
    Book Value Per Share$38.77
    Tangible Book Value$105.43M
    Tangible Book Per Share$33.16
    Total Assets$128.50M
    Total Liabilities$5.22M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $609.00K of capital spending, operating cash flow left $10.86M of free cash flow.

    Operating Cash Flow$11.47M
    Capital Expenditures$609.00K
    Free Cash Flow$10.86M
    FCF Per Share$3.81
    Depreciation and Amortization$1.96M
    Dividends Paid$3.94M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 29.93%, against a 5-year average of 34.52%.

    Gross Margin56.17%
    Operating Margin29.93%
    Pretax Margin37.16%
    Net Margin30.48%
    EBITDA Margin42.72%
    EBIT Margin37.16%
    FCF Margin31.10%
    Gross Margin (5Y Average)60.11%
    Operating Margin (5Y Average)34.52%
    Net Margin (5Y Average)31.60%

    Growth

    Revenue fell 9.68% a year over 3 years, and EPS 8.30% a year.

    Revenue Growth (3Y CAGR)-9.68%
    Revenue Growth (5Y CAGR)-1.80%
    EPS Growth (3Y CAGR)-8.30%
    EPS Growth (5Y CAGR)-8.25%
    FCF Growth (3Y CAGR)-11.03%
    FCF Growth (5Y CAGR)-5.77%
    Operating Income Growth (3Y CAGR)-16.79%
    Book Value Per Share Growth (2Y CAGR)+2.70%
    Tangible Book Per Share Growth (2Y CAGR)+3.92%

    Revenue and profit by year

    Dividends and Yields

    UTMD pays out 34.38% of earnings as dividends.

    Dividend Per Share (Annual)$1.24
    Dividend Yield1.72%
    Payment ScheduleQuarterly
    Dividend Growth (3Y CAGR)+1.69%
    Dividend Growth (5Y CAGR)+1.72%
    Payout Ratio34.38%
    FCF Payout Ratio36.28%
    Earnings Yield4.63%
    FCF Yield4.74%
    Buyback Yield0.83%
    Shareholder Yield2.55%

    Full dividend history

    Peer Position

    Against 6 similar companies, UTMD has the 4th highest P/E.

    P/E Ratio21.6x vs 21.4x median
    P/S Ratio6.6x vs 2.3x median
    ROIC6.74% vs 8.86% median
    Revenue Growth (Trailing 4 Quarters, YoY)-9.62% vs +8.63% median
    Dividend Yield1.72% vs 0.00% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About UTMD

    What is UTMD's market cap?

    Utah Medical Products has a market cap of $206.03M. Its enterprise value, which adds debt and subtracts cash, is $121.01M.

    What is UTMD's P/E ratio?

    Utah Medical Products has a trailing P/E ratio of 21.6x.

    How many shares of UTMD are outstanding?

    Utah Medical Products has 3.18M shares outstanding. The count is down 0.84% from a year earlier.

    Does UTMD pay a dividend?

    Yes. Utah Medical Products pays $1.24 a share a year, a dividend yield of 1.72%.

    How much debt does UTMD have?

    Utah Medical Products has $180.00K of total debt and $85.20M of cash and equivalents, a net cash position of $85.02M.